Pat is the head of the Equine Studies Group at Waltham Petcare Science Institute and an internationally renowned authority on equine nutrition from both veterinary and academic perspective.
Her courses, book publications and webinars are aimed at providing practising equine vets with the latest knowledge and essential know-how on equine nutrition, whether for performance horses, leisure animals or the retired family pony.
Earlier this month Pat was one of several speakers at the British Equine Veterinary Association’s CPD course: From superfoods to supplements: How to know more than the owner.
Earlier this year she co-edited and co-authored two chapters of Veterinary Clinics Equine Practice: Nutrition: 1) What would be good for all veterinarians to know about equine nutrition, and 2) Nutritional considerations when dealing with an obese adult equine.
Next month she will chair a panel discussion titled Nutritional Management of the Competitive Equine Athlete for Vets through VetPD.
In the autumn she will be one of several speakers at the Mars Equestrian Equine Veterinary Continuing Education Series focusing on senior, obese and laminitic horses.
For more information, visit: www.spillers-feeds.com
The webinar will take place at 11am and will be repeated at 7.30pm for those who are unable to listen during the day.
Hosted by Zoetis vet Dr Wendy Talbot the session will last for approximately an hour and equates to 8 AMTRA CPD points.
Wendy will explain the current situation and recommended approaches to help slow resistance.
The webinar will conclude with a live Q&A to give everyone the opportunity to discuss any queries, concerns or common questions they hear from their customers with Wendy.
Zoetis Equine Product Manager, Penny McCann said: "Our webinars continue to be very well received.
“This one is particularly important as it explains the important new thinking around the use of anthelmintics in order to address the serious challenge of resistance.
"It’s a must for all those involved with prescribing.”
To book the 11am webinar: https://register.gotowebinar.com/register/6163460189961597967 To book the 7.30pm webinar: https://register.gotowebinar.com/register/6394015684169009164
The practice is now accepting dental referrals, including for dental, oral and maxillofacial surgery.
Hannah said: “I am proud to join the Fitzpatrick Referrals team to extend their referral offering to include this very important aspect of small animal veterinary treatment.
"Working alongside a world-class team with state-of-the-art facilities is a fantastic opportunity.”
https://www.fitzpatrickreferrals.co.uk/services/dentistry/
Eurovet has launched Octacillin Pig, a water-soluble amoxicillin powder for treating pneumonia caused by Actinobacillus pleuropneumoniae and meningitis caused by Streptococcus suis.
Octacillin is widely used in poultry and has recently been approved for use in pigs. Eurovet says Octacillin Pig is ideal for delivery via automatic water systems, as it dissolves completely in hard or soft water and remains stable in solution for 12 hours. It has a withhold period of 2 days.
Pneumonia caused by Actinobacillus pleuropneumoniae tends to affect pigs at 8-16 weeks of age and has a very short incubation period of just 12 hours.
Octacillin Pig will be available from early March.
For further information call 01223 257933.
The traditional approach is to use anatomical knowledge to inject pain relief in the area of the nerves to be blocked.
Liz is leading a move away from this approach to a more precise method which uses ultrasound guidance to visualise the nerves, allowing the local anaesthetic to be placed directly around the nerve itself.
For some nerve blocks, it is possible to block just the sensory branches of nerves, which means pets can walk better immediately after surgery while not feeling any pain.
Liz, a past president of the Association of Veterinary Anaesthetists, said: “Local analgesia is now at the forefront of our post-operative care and reliably improves the quality of a pet’s recovery and reduces the need for opioid pain relief, which can cause side effects.
“We’re using the latest techniques to deliver the nerve-blocking anaesthetics to exactly where they’re needed.
“For many of the nerve blocks, the use of ultrasound guidance allows more precise delivery and a complete blockade of the sensory nerves, which is why, here at Paragon, we’ve invested in state-of-the art ultrasound machine designed specifically for superficial and deep nerve blocks.
“This means we can provide more effective immediate post-operative analgesia for our patients and minimise the need for further pain killers.
“The nerves can be directly visualised and local anaesthetic directly placed around the nerve bundles.”
Liz is keen to highlight the advantages of the increased use of local anaesthesia in the treatment of animals. She added: “We’re hoping we’ll soon be able to publish some clinical research on the use of some of the blocking techniques used to demonstrate our clinical impression of their effectiveness in patient management.”
The two-year study aims to better understand the impact of the disease on horses’ and ponies’ quality of life and is hoped to improve monitoring and decision-making regarding treatment.
In particular, the study aims to develop a validated equine quality of life tool to assess the impact of the condition on an individual horse’s quality of life objectively.
This, it is hoped, will help support decision-making related to treatment and euthanasia options for horses and ponies diagnosed with PPID.
The research team is led by Aline Bouquet, PhD Candidate and Research Assistant, and supported by Professor Nicola Menzies-Gow, Professor in Equine Medicine and Professor Christine Nicol, Professor of Animal Welfare.
Participants can have horses and ponies with PPID as well as those without the condition and they must be older than ten years of age (the horses, that is)
The survey will take no longer than 15 minutes to complete, providing an assessment of the animal’s quality of life, clinical signs associated with PPID and any additional veterinary-related problems.
https://rvc.uk.com/PPID-survey-2023-stage1
https://www.rvc.ac.uk/research/projects/objective-assessment-of-the-quality-of-life-of-equines-with-pituitary-pars-intermedia-dysfunction
The University of Surrey has announced that it is to launch a new school of veterinary medicine in 2014.
According to the University, the new school will embrace the 'One Health - One Medicine' philosophy and will include the development of a unique research-led veterinary medicine degree programme with an emphasis on research, veterinary pathology and livestock medicine.
The new school will be based at the University of Surrey's Manor Park site in Guildford, in order to encourage collaboration of students and staff from different disciplines, with those studying towards a veterinary medicine qualification being exposed to engineering and physics as well as receiving training in core business skills.
The new School of Veterinary Medicine at Surrey will be delivered through collaborations with key partners including: the Animal Health and Veterinary Laboratories Agency (AHVLA), the BBSRC Pirbright Institute, the Veterinary Medicines Directorate (VMD), Fitzpatrick Referrals, Liphook Equine Hospital and Westpoint Farm Vets. The University says it is looking to extend its relationships with regional veterinary practices over the coming year.
Students will also be exposed to global issues concerning animal health through the University Global Partnership Network (UGPN), a trilateral agreement between Surrey, North Carolina State and São Paulo Universities through teaching collaborations, summer scholarships and research exchanges.
Professor Lisa Roberts, Dean of the Faculty of Health and Medical Sciences at the University of Surrey, said: "As a research-intensive University we have the expertise, reputation, technical and business skills which our students can benefit from, allowing us to train the veterinary leaders of the future. Combining state-of-the-art facilities, our unique partnerships and a campus location, the new School will provide a stimulating environment not only for undergraduates, but for the professional development training of qualified veterinary surgeons."
Professor John Fazakerley, Director of The Pirbright Institute, said: "This is good news for the UK veterinary research community. The Pirbright Institute currently works in close collaboration with the University of Surrey on research that benefits animal health and welfare; we very much look forward to building on this established and growing association as the new school of veterinary medicine is launched. There is an important place for trained veterinarians in scientific research and we are delighted that the University has decided to emphasise these areas in particular."
Professor Andy Durham of the Liphook Equine Hospital said: "The new School of Veterinary Medicine development programme at the University of Surrey is ideally timed to provide an alternative to the traditional veterinary education and to respond to the demands of a changing profession with fresh plans, ideas and enthusiasm. Enticing newly developed facilities make Guildford an excellent student town and with several collaborative specialist partners within the locality the new School of Veterinary Medicine is perfectly placed geographically to provide a veterinary education fitting for the 21st century."
The University is also in consultation with the Royal College of Veterinary Surgeons. Freda Andrews, Head of Education at the RCVS, said: "We were pleased to meet Professor Sir Christopher Snowden, President and Vice-Chancellor and his colleagues from the University of Surrey recently, and interested to hear their proposals to develop a new School of Veterinary Medicine. We will be working with them over the coming months to develop a timetable for considering the new programme against our accreditation standards. The monitoring process will take a number of years."
The University says it has already laid the foundations for the new School through its expansion of teaching and research activities in its Faculty of Health and Medical Sciences, including the launch of the BSc programme in Veterinary Biosciences in 2009 and in October of this year a new MSc in Veterinary Microbiology. A new MSc in Veterinary Pathology is also currently under development.
The University says that over the next 12 months it will be recruiting new academic staff, attracting the first cohort of students and beginning building works in preparation for the first cohort of students in 2014.
Brand Manager Dr Amy Scott said: "Because pain is often very difficult for owners to spot, the website highlights some of the common signs that indicate their cat or dog is suffering.
"We have also included a range of additional measures that owners can take to improve the quality of life and maintain the joint health of their pet once Metacam has been prescribed. These include weight management, regular and gentle exercise and alternative therapies such as hydrotherapy or the use of joint supplements such as Seraquin."
The website highlights common painful conditions such as arthritis, as well as more acute scenarios such as post injury or surgery. It also describes the changes in behaviour owners should be aware of that could indicate their pet is in pain, for example reluctance to exercise, change in appetite, displays of aggression or depression.
Amy added: "The correct use of NSAIDs is also an important consideration for effective pain management. To help with this, the website contains a section on Metacam administration for owners, featuring a short video on accurate dosing and treatment."
Dr Henry faced one charge, that in January 2020 she wrote and/or signed an undated letter confirming that a ewe had died in transit to the surgery due to dystocia and peri-parturient stress, when in fact she had euthanised the animal at the veterinary practice the day before. The letter, which was addressed 'To whom it may concern’, was on practice letterheaded paper and signed "Louise Henry MRCVS".
The second part of the charge outlined that her conduct concerning the letter was dishonest.
The Committee heard that the ewe was lambing and brought to the practice by a client. Dr Henry was on-call at the time and advised a Caesarean section. The client agreed and Dr Henry delivered two live lambs and one dead lamb.
Dr Henry was concerned about the welfare of the ewe post-surgery because of the risk of peritonitis and advised that the ewe should be euthanised.
The client agreed to the ewe being euthanised and then asked Dr Henry to write a letter in which it was stated that the ewe had died in transit on route to the practice. Dr Henry agreed to write the letter in which she falsely certified that the ewe had died in transit.
The letter came to light when the practice director found it in an insurance file. The practice arranged an investigatory meeting with Dr Henry where she admitted that writing the letter was an error of judgement. When asked about her conduct, Dr Henry explained that the client had subsequently been dissatisfied with the letter she had written and asked her to change it. She refused to amend the letter and told him that it was wrong of her to have written it in the first place and that she regretted having done so.
Dr Henry told the Committee that she valued integrity very highly and that she was deeply ashamed that she had been prepared to write the dishonest letter.
The Committee heard several testimonials from people who had worked with or studied alongside Dr Henry, who all attested to her skill as a veterinary surgeon and that they had no concerns about her integrity and honesty. She self-reported her actions from January to the RCVS and from the outset admitted the facts of the charge. During the hearing, Dr Henry submitted that her action of dishonest false certification amounted to disgraceful conduct in a professional respect.
Dr Martin Whiting, chairing the Committee, and speaking on its behalf, said: “The Committee considered that, in this case, the aggravating features were limited and the mitigating factors extensive. There was no premeditated dishonesty or financial gain involved, there was no actual harm or risk of harm to an animal or human and this was a single incident in an otherwise unblemished 13-year career. The Committee found that the shame and remorse expressed by Dr Henry were entirely genuine. Her conduct on this occasion was entirely untypical of her practise.
“After careful consideration, the Committee concluded that the substantial mitigating features permitted it to take the somewhat unusual course of issuing a reprimand in a case involving dishonesty. In taking this course, the Committee attached significant weight not only to the isolated nature of the event but also to the genuine insight shown by Dr Henry and the lasting impact this event has had upon her. In the Committee’s assessment, a reasonable and fully informed member of the public would, in this particular case, regard a reprimand as a sanction which protected the public interest in the profession and upheld its standards.”
The full documentation for the hearing can be found at www.rcvs.org.uk/disciplinary
Genitrix has repackaged its Dentagen plaque prevention chews to provide added value and convenience to pet owners.
Packs of the chews, launched in 2008 as part of Genitrix' Dentagen dental range, will now be available in 'one month' packs in response to customer feedback. The new, bigger value packs will also be priced more cost-effectively and will offer environmental benefits as the amount of packaging is reduced.
Dentagen dental chews are impregnated with a plant extract called RF2 which enables them to act as an 'anti-biofilm' treatment, modifying the membrane of oral bacteria to prevent them from producing plaque. The chews, which come in two sizes for large and small dogs, are designed to be given on alternate days and form part of the unique Dentagen Dental Care Programme. Earlier this year, Genitrix also launched Dentagen Aqua, an innovative water additive treatment to control plaque and prevent bad breath in cats and dogs.
The new size packs of Dentagen chews, which will be available exclusively through veterinary channels, cost £6.35 for a pack of 14 small chews (one month's supply) and £8.09 for 14 large chews.
Jacqui Molyneux, SPVS President Elect, has announced details of the work she has been involved in to radically restructure and improve the training of veterinary nurses in the UK.
For the last 10 years the VN qualification has involved candidates sitting for an NVQ in veterinary nursing. This NVQ is however being phased out by the Government, whatever party that may be, from next September. The RCVS is therefore taking this opportunity to put in place a viable alternative qualification to improve and build upon the current structure.
Jacqui said: "We are coming from the standpoint that, worryingly, there is a dire shortage of RVNs available for practices to employ. If we do not take this opportunity to do something now, the situation will in all likelihood deteriorate even further.
"I chair a working party convened in May which has been looking at current VN training and how to improve it. There was an initial written period of information gathering followed by three full days of face-to-face consultation meetings with invited interested parties in July and September. This period of consultation has resulted in a proposal being put forward.
She added: "The proposals are radical and in some ways controversial but have been put together in response to the feedback we have received so far. I must, however, reiterate that it is, at this stage, a proposal and we are still in a consultation period.
"At the end of the period we will have another working party meeting and reassess the proposal. This will then go to the Awarding Body Board and on to both VN council and RCVS council for full approval. I hope we will end up with a scheme that reflects the vital role nurses play in a modern veterinary practice."
The consultation document can be found here.
The BSAVA has announced that Nottingham Trent University will be the accrediting body for the new Postgraduate Surgery and Medicine Certificates being launched in January 2012.
BSAVA says the planning for this new education initiative has been exhaustive, ensuring that the needs of the profession and the individual vet can be met by a provider with an excellent legacy in veterinary education. And also, an organisation with a genuine interest in seeing the highest scientific standards are matched by a relevant, cost-effective, and accessible programme that fits with life in practice today. To that end, finding the right validation partner was a crucial part of the planning.
Dr Frances Barr, BSAVA Academic Director, said: "This is an exciting new venture in postgraduate CPD, and will ultimately lead to qualifications which are achievable for those in practice and directly relates to their experience. Yet of course, these qualifications must remain challenging enough to merit the respect of the profession and meet the standards of the clinical excellence we all want to see.
"We are confident that BSAVA is the provider to deliver just this, but finding the right partner to validate the programmes was especially important. We want to know that we can move forward with the support and backing of an accrediting body that encourages academic excellence and at the same time understands the need to remain relevant and engaging to busy professionals."
These new qualifications are primarily aimed at veterinary surgeons in small animal practice, who have a particular interest in small animal medicine or surgery. So busy professionals is exactly who they are designed for. This appeals particularly to BSAVA President Andrew Ash, who as well as running the Association heads a six site practice in Sussex. He said: "As an employer I see more and more people who want some recognition for the time they spend fulfilling their professional CPD requirement - and with these discipline-based certificates I can see a way that at any point in your career you can now be rewarded with not only a greater breadth of knowledge and confidence, but with a certificate to show for your efforts.
"I am a great advocate of continual education, and having made a commitment to postgraduate study myself in the past I know how important supported learning is, and how essential it is to have an environment that both acknowledges your other commitments and gives you the support to achieve your ambitions. We are determined to do that.
"Of course I am delighted that this is being launched in my year as President. I am even more delighted that we have Frances Barr to lead this - her experience and enthusiasm is as impressive in this role as it was when she was BSAVA president".
Gill Richards, Director of Professional Development at Nottingham Trent chaired the validation visit at Woodrow House. She said: "Nottingham Trent is especially interested in working with professions in this way to help ensure the quality of provision on postgraduate education for people at all stages of their careers. It was our pleasure to confirm validation today and we look forward to working with the team at BSAVA. It is unusual for anyone to receive the number of commendations that were made today, and what has impressed us most about BSAVA is the impressive quality of the teaching team and materials, and the innovative response to meeting a national demand for a course of this quality".
Enrolment will opening October. The courses will be limited to 30 in each programme. Anyone interested in enrolling for one of these certificate programmes can email academicdirector@bsasva.com or call 01452 726700.
Vetoquinol UK Ltd has launched a new flea and tick treatment for cats and dogs.
Flevox is a spot-on solution containing fipronil and comes in unique pack sizes of either single pipettes or large clinic packs of 36.
Product Manager Helen Walker said: "With only 55% of pet owners buying their flea and tick treatment from the vet, we recognise there is a huge opportunity to develop and grow this essential market. In the modern age the consumer expects maximum flexibility, and that is what we aim to provide with Flevox.
Whether it be persuading the price-conscious customer away from buying their flea treatments in supermarkets and the internet, or encouraging those who don't treat their pet at all to give it a try without breaking the bank, we're confident we can help grow flea treatment sales in practice."
Vetoquinol says it is supporting the new product with a range of materials dedicated to veterinary surgeries, providing incentives to encourage client bonding and repeat business with your practice.
Helen continued: "We have also teamed up with the fantastic charity Dogs for the Disabled by making a donation for every pipette of Flevox sold. We're really looking forward to raising the profile of this organisation where these amazing dogs give life changing independence to disabled people. We're confident the donation will strike a chord with clients and really engage them with the charity, the Flevox brand and the practice".
To find out more, contact your Vetoquinol territory manager or visit http://www.vetoquinol.co.uk/
Luke will receive his award at the 2016 WSAVA World Congress, which takes place from 27-30 September in Cartagena, Colombia, where he will also give a lecture on his work, entitled ‘One Mission’.
The WSAVA Global One Health Award is presented by the WSAVA’s One Health Committee (OHC) to an individual who has promoted an aspect of One Health relevant to small companion animals.
Luke graduated from Bristol University in 1999 and is based in his New Forest surgery, Pilgrims Veterinary Practice. In 2003, he set up Worldwide Veterinary Service (WVS), a charity providing veterinary aid around the world, followed, in 2013, by sister charity, Mission Rabies, which is leading the battle against canine rabies and works closely with the WSAVA’s charitable Foundation. Luke is CEO of both organisations and has raised more than four million pounds to support the charities’ projects around the world. He lectures internationally on animal welfare and veterinary subjects and, in 2014, was asked by the World Health Organisation (WHO) to sit on an expert panel for the International Control of Neglected Zoonotic Diseases based on his rabies work globally.
Professor Michael Day, Chair of the WSAVA OHC, said: "The current most significant example of the importance of a One Health approach to disease control relates to the global fight against canine rabies - a disease that continues to cause an estimated minimum 59,000 human deaths each year. Luke is a world leader in this global fight. Mission Rabies runs mass vaccination campaigns and provides public education in Asia and Africa, having now vaccinated almost 400,000 dogs, spoken to over 500,000 schoolchildren and successfully controlled rabies in selected target areas.
"The Mission Rabies programme is grounded in solid evidence-based science, with the field data collected having now generated the first high-class scientific manuscripts. Luke is a truly inspirational and charismatic leader who believes in simply getting on with the job at hand. The achievements of Mission Rabies and its sister charity, Worldwide Veterinary Service, readily show that even the greatest global health challenges are not insurmountable."
Luke said: "It’s a huge honour to receive this Award and I accept it on behalf of an amazing team - without whom - the projects would be impossible. It’s an utter privilege to be a part of the veterinary profession and fighting diseases like rabies is an incredible opportunity to champion both animals and people – something we can all identify with. I’m totally indebted to WSAVA and the international veterinary community, whose support has been overwhelming, and it is only with this unity, that we can keep driving forward – and winning."
The support pack is available now for existing stockists; others can sign up for a pack (whilst stocks last) at the London Vet Show in November, where Lintbells will be at stand U50.
According to the company, an estimated 15% of canine cases presented at first opinion practices are musculoskeletal and cats are also commonly affected.1
The Mobility Matters support materials are designed to help practices communicate the issues to clients, both in the waiting area and consulting room and online. There are also resources to help behind the scenes with setting up the clinics, including the new guide.
Gemma Cunningham, Lintbells Product Marketing Executive said: "We’re keen to bring attention to nurse-led clinics, which are not just great for patients but great for business too. Measurable outcomes include client satisfaction, incremental sales and improved patient comfort or quality of life. We’ve taken into account existing barriers based on what veterinary teams have told us and created the pack to address those needs. Our Mobility Matters referral cards, which help vets signpost clients to the clinics are a brilliant example of how the pack can help teams work more effectively together."
For more information, contact Lintbells on 01462 790886.
Reference
Vétoquinol, manufacturer of Epiphen (phenobarbital), for the control of epilepsy in dogs, has announced the launch of a new starter pack for clients that are embarking on treatment.
The starter packs contain a variety of support materials designed to help owners better understand the condition and its treatment. They sit alongside other support given by the company, which includes an 'Ask the Expert' helpline through which Epiphen veterinary customers can speak to a neurology specialist at The Animal Health Trust in Newmarket, where Vetoquinol sponsors a neurology clinician.
Abbie King, Product Manager for Epiphen, said: ''Our 'Ask the Expert' helpline is a successful service that has been running for several years. 30% of the calls to Vetoquinol's technical team relate to this challenging condition meaning there are few queries our technical team have not tackled before. If extra help is necessary we have an excellent working relationship with The Animal Health Trust and regularly refer cases to them for further advice. We are very proud of this service and are delighted to be able to continue to provide this helpline for our Epiphen clients.''
To use the 'Ask the Expert' service, or order the support materials, ring 0800 1698197. Alternatively visit: www.vetoquinol.co.uk or www.epiphenonline.co.uk.
The VetDebt Recovery Compass tool provides a way for practices to understand how outstanding payments affect their cash flow and practice value, and what steps to take next.
Mike Brooks, Chairman at DSL UK (pictured), said: “The VetDebt Recovery Compass offers a quick and easy way to see the true financial impact of unpaid debt.
"By making this information free and accessible to everyone, we hope to empower veterinary teams to take control of their finances.
DSL says that the new tool, which is available at www.dsluk.net, allows practices to see both the immediate recovery potential and the long-term value impact of their debts in less than 30 seconds.
The calculator also provides a species-specific breakdown, helping to identify where debt issues may be most significant and where to target first.
Mike has also appeared on the Federation of Independent Veterinary Practices (FIVP) Practice Matters Podcast, discussing how practices can better manage the topic of debt: https://fivp.org.uk/ep023-fivp-practice-matters-at-spvs-the-farm-vet-journey-practice-debt.
Norbrook has launched Loxicom 0.5mg/ml oral suspension for small dogs, indicated for the alleviation of inflammation and pain in acute and chronic musculo-skeletal disorders.
Loxicom Oral Suspension comes in a clear 15ml bottle which allows vets and clients to monitor levels of the product and re-order when necessary.
Loxicom 0.5mg/ml for Dogs comes with two sizes of syringe, a 1ml syringe graduated from 0.25kg-5kg to treat even the smallest of dog breeds accurately, and a 5ml syringe graduated from 1kg-25kg to treat small and medium dog breeds. The syringes plug securely into the bottle to ensure a tight-fitting connection and minimal leakage when administering the product.
This new oral suspension joins the range of 1.5mg/ml oral suspensions for Dogs and 5mg/ml injections for Dogs and Cats, launched in 2009, and the 0.5mg/ml oral suspension for Cats launched earlier this year at the BSAVA Congress.
Invicta Animal Health has launched a new identification service for ChroMyco Duo dermatophyte kits in partnership with Axiom Veterinary Laboratories.
Veterinary practices can now send positive ChroMyco plates to Axiom and receive a species identification report for the specially discounted price of £8.00.
Rob Watkins, Managing Director of Invicta Animal Health said: "We are delighted to launch this service in response to customer feedback. This enables practices to gain a positive dermatophyte diagnosis in as little as three to six days so that treatment can be commenced promptly. Then, by sending the plate to Axiom, the actual species can be subsequently identified.
Axiom, with its innovative microbiology department and dedication to quality combined with its reliable network of courier services and postal processing systems are the ideal laboratory to provide this service".
Submission forms are available free of charge from Invicta Animal Health 01403 791313. ChroMyco Duo dermatophyte test kits are available from wholesalers and priced at £25.00 for 5 kits.
Carried out by the Royal Veterinary College (RVC), the Animal Health Trust (AHT) and Rossdales Equine Hospital, the study also revealed that the groups particularly at risk were native pony breeds and their crosses, as well as horses and ponies with a history of laminitis and those with lameness or soreness after routine hoof care.
This research, funded by World Horse Welfare, comes from the first ever online study that collected information on laminitis from a group of owners in real time.
The researchers say that the study is also the second largest to identify weight gain as a risk factor for laminitis. Data was collected from the owners of 1,070 horses and ponies in Great Britain, who reported their animal’s management, health and estimated weight via online questionnaires for 29 months.
Owners were encouraged to use a custom weight tracking tool designed by the study/research team to help regularly track changes in their animal’s weight and body condition. The uptake of this tool was high, with over half of participating owners using it.
The tool is freely available at: www.aht.org.uk/research/lameness/laminitis.
Other study findings included:
A high risk of laminitis was present in horses shod or trimmed at intervals of more than 8 weeks, and in those that took a long time to return to soundness after a bout of laminitis.
Diet, grazing management and health were factors closely associated with the development of laminitis and will be the subject of future investigation.
Researchers also noted that weight gain often occurred unintentionally, even when owners were aiming for their animals to maintain or lose it. This reiterates the need to consistently record weight and body condition in order to prevent undesirable weight gain.
Dr. Dee Pollard of the AHT, one of the study’s chief authors, said: "This is one of the largest, and the first, online laminitis studies where we collected regular information from the same group of owners in real-time. We assessed the relationship between laminitis and many potential management and health factors and identified those more likely to be present before a laminitis episode was reported.
"We now have good evidence to develop laminitis prevention guidelines, and a number of different avenues to explore in the future. We cannot emphasise enough how important systematic and regular weight and body condition monitoring are. It’s very easy to miss weight gain when you are just relying on your eyes and you see your horse or pony every day. You need to get hands on, feel for the fat deposits and take measurements, remember the figures don’t lie!"
Norbrook Laboratories has launched Cefimam DC intramammary ointment, a new dry cow preparation containing the 4th generation cephalosporin, cefquinome.
The company has also released a Polish language version of its Best Practice Guide for On-Farm Mastitis Control, in response to demand from producers with non-English speaking farm-hands.
Norbrook vet Chris Geddes said: "I believe this is the first time that such a guide has been produced to cater for farm-hands of a different nationality working within the UK. Good mastitis management starts with good education; giving everyone on the farm the same opportunity for learning the best techniques for prevention means that we help minimise incidences of mastitis, which costs the dairy industry millions of pounds in lost revenue every year.
"This prevention includes a thorough and consistent approach to dry cow management. The early drying off period is often a risky time, when pre-existing subclinical infections can bed-in. The cow is also at increased risk of gaining new infections due to lack of udder hygiene procedures that would normally occur at milking, and weakened immunity as she approaches calving. Our new cefquinome preparation is a valuable addition to have in the treatment armoury for dry cow management. It has broad-spectrum activity and high cellular penetration to help tackle hard-to-manage cases with the aim of returning to maximum productivity by the start of the milking season."
Cefimam DC will be available at all veterinary wholesalers in packs of 24x and 120x 8g intramammary tubes. Vets can obtain both English and Polish versions of the Best Practice Guide for On-Farm Mastitis Control from Territory Managers.
For further information or copies of the Best Practice Guide for On-Farm Mastitis Control in English or Polish, contact your Territory Manager or call Norbrook GB head office on 01536 741 147.
Dr Vlad Butnaru faced two charges, the first of which was that in May 2021, he had signed a passport and/or passport application for a horse and electronically signed a declaration stating that he “had read the above microchip, which had previously been implanted for the animal” when, in fact, the microchip had not been inserted into any horse and he had not read it.
The second charge was that, in relation to the matters set out in the first charge, Dr Butnaru’s signed declaration was false, and that he had acted dishonestly and misleadingly, he risked undermining procedures designed to promote animal welfare, and failed to take sufficient steps to ensure that the microchip number recorded for the horse was accurate.
Dr Butnaru admitted the first charge on all counts, and that the declaration he had signed was false.
He also admitted that his conduct was misleading and that he had failed to take sufficient steps to ensure that the microchip number recorded for the horse was accurate.
However, he denied that his conduct had been dishonest and that he had risked undermining a procedure designed to promote animal welfare.
In its decision, the committee noted that Dr Butnaru kept introducing new versions of what happened for the first time at the hearing and changed his account as he went along, as well as being evasive when answering questions.
The Committee therefore felt that Dr Butnaru could not be considered to be a reliable witness, and whilst it did not know the true reason why he was prepared to sign a false declaration on a passport application, it was satisfied that he'd made a false declaration dishonestly.
The Committee also found that Dr Butnaru had failed to take sufficient steps to ensure that the microchip number recorded for the horse was accurate as, if the passport had been issued on a false premise because of misleading information provided by Dr Butnaru, then it could not function as it was meant to which, in the Committee’s view, clearly risked undermining procedures designed to protect animal welfare.
The Committee found that Dr Butnaru had breached the parts 6.2 and 6.5 of the Code of Professional Conduct, as well as Principle 1 of the 10 Principles of Certification, namely that ‘a veterinarian should certify only those matters which: a) are within his or her own knowledge; b) can be ascertained by him or her personally; c) are the subject of supporting evidence from an authorised veterinarian who has personal knowledge of the matters in question; or d) are the subject of checks carried out by an Officially Authorised Person (OAP).’
The Committee found there were no mitigating factors.
Aggravating factors, on the other hand, were that Dr Butnaru had participated in premeditated misconduct, made financial gain from his actions as he was paid to make the false declaration, abused his professional position, and showed blatant or wilful disregard of the Horse Passport System and of the role of the RCVS and the systems that regulate the veterinary profession.
The Committee found that all proven charges amounted to Disgraceful Conduct in a Professional Respect.
On considering the sanction, the Committee once again considered the aggravating factors, as well as additional mitigating factors in that Dr Butnaru had no previous disciplinary history, showed limited insight by admitting to some of the charges, showed expressions of remorse, and was provided with a positive testimonial.
Paul Morris, chairing the Committee and speaking on its behalf, said: “The Committee was cognisant of the importance of a veterinary surgeon’s signature on any document.
"This should have been obvious to any veterinary surgeon, but particularly someone of Dr Butnaru’s 11 years’ experience (at the time of signing).
"The Committee was well aware of the impact and ramifications for Dr Butnaru of any decision to remove him from the Register, but had to weigh his interests with those of the public.
“In doing so it took account of the context and circumstances of the case, all matters of personal mitigation, Dr Butnaru’s previous unblemished record and the need to act proportionately.
"However, the Committee was of the view that the need to uphold proper standards of conduct within the veterinary profession, together with the public interest in maintaining confidence in the profession of veterinary surgeons and protecting the welfare of animals, meant that a period of suspension would not be sufficient.
"His actions were fundamentally incompatible with remaining on the Register and thus the only appropriate and proportionate sanction in all the circumstances of this case was that of removal from the Register.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
Dechra Veterinary Products has reduced the price of two key products in its Veterinary Essentials range to help practices respond to the challenging economic climate.
Atipam 5 ml is now the same price per ml as Atipam 10ml. Used for the reversal of the sedative effects of medetomidine and dexmedetomidine in cats and dogs, practices can now choose the size that suits them best. Additionally, during January, for every 15ml purchased an extra 5ml will be provided to practices free of charge.
Thyroxyl, used for the treatment of hypothyroidism in dogs, has also been reduced in price by 15 per cent. Practices that include Thryoxyl as part of the newly introduced Essential Purchase Plan can also make further savings.
To find out more about the Veterinary Essentials range, including further costs savings with an Essentials Purchase Plan and free margin development advice, call Liz Rawlings on 01743 441632.
Hill's Pet Nutrition is offering veterinary surgeons, vet students and nurses in the UK an opportunity to look round its Pet Nutrition Centre in Topeka, Kansas, via a live webcast to be delivered at 7pm on Tuesday 11th January 2011.
To join the webcast, which will last around 1.5 hours, go to http://www.fc-tv.com/webcast/keystone/hills/jan-11-11 and enter the password pnctour. This event is specifically for veterinary surgeons, veterinary students and veterinary nurses only.
Tim Dobbins, Associate Veterinary Affairs Manager said: "We look forward to our colleagues joining us for this special live webcast and hearing some of the latest thinking that explains the science behind some of our most exciting products."
A research project funded by The Horse Trust has made important discoveries about how two peptides regulate the inflammatory response in horses. This knowledge could help with the development of improved anti-inflammatory drugs, which are used to treat a wide range of conditions in horses.
The research project was led by Professor Fiona Cunningham at the Royal Veterinary College in Hertfordshire and Dr Karen Rickards at the Donkey Sanctuary in Sidmouth, assisted by Dr Andrew Brooks at the RVC, and by Dr Kirstie Pickles, now at the Royal (Dick) School of Veterinary Studies in Edinburgh.
Inflammation is associated with a wide range of equine diseases, including recurrent airway obstruction, laminitis and sweet itch. Anti-inflammatory drugs, such as glucocorticosteroids, mainly work by blocking the formation and/or actions of compounds produced in the horse's body that cause inflammatory responses. However, these drugs are not always effective and can have unwanted side effects.
This research, funded by The Horse Trust, aimed to find out more about two naturally-occurring peptides - chains of amino acids that are shorter than proteins - known as annexin-1 and CXCL8. Both have been shown to affect the inflammatory response but little research has been done on their effects in horses. In the long term, knowing more about these compounds could help in the development of new anti-inflammatory drugs with fewer side effects.
During inflammation, neutrophils (a type of white blood cell) stick to the cells lining blood vessels and migrate into inflamed tissue, where they ingest and break down harmful agents. Using techniques that mimic these events, CXCL8 was found to cause adherence and migration of horse neutrophils. However, when it was used in combination with another pro-inflammatory substance, neutrophil migration and adherence were markedly decreased. This suggests that attempts to reduce inflammation by blocking the actions of CXCL8 might not be as beneficial as had been thought.
At the start of the project, the researchers had no information about horse annexin-1, other than its gene sequence, so their first step was to develop a method to detect the peptide in white blood cells. They established that it was present and, as horse annexin-1 has not yet been synthesised, they used a synthetic peptide derived from annexin-1, Ac2-26, to look at the effects on horse neutrophils.
They found that Ac2-26 decreased neutrophil adherence and migration in response to other pro-inflammatory compounds, although at high concentrations the peptide itself caused some cell activation, thereby increasing inflammation. They also found that dexamethasone (a glucocorticosteroid) increased the levels of annexin-1 in cells, indicating that, as in humans, this class of drugs is likely to act in part through the formation of annexin-1.
These findings suggest that the use of compounds which mimic the actions of annexin-1 may have limitations as anti-inflammatory drugs. As glucocorticosteroids partly work by forming annexin-1, further research is needed in order to find out how annexin-1 will act in the horse's body and establish how its formation contributes to the beneficial effects of these drugs.
Professor Cunningham said: "This Horse Trust-funded research has resulted in some very interesting findings about how inflammatory cells are regulated in horses. The receptors that annexin-1 and CXCL8 act upon could be targets for new equine inflammatory drugs, but more research is needed first to fully understand their actions and how they produce these effects."
The team's research has been accepted for publication by the journal Veterinary Immunology & Immunopathology.